TITLE

Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients

AUTHOR(S)
Kim, Kihyun; Kim, Seok; Voelter, Verena; Suh, Cheolwon; Yoon, Sung-Soo; Lee, Je-Jung; Kwak, Jae-Yong; Ryoo, Hun-Mo; Kim, Yang; Moon, Joon; Park, Seong; Kim, Sung-Hyun; Mun, Yeung-Chul; Kim, Jin; Eom, Hyeon-Seok; Jo, Deog-Yeon; Jun, Hyun; Kim, Ki-Hwan; Lee, Jeong-Ok; Lee, Jae
PUB. DATE
January 2014
SOURCE
Annals of Hematology;Jan2014, Vol. 93 Issue 1, p113
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.
ACCESSION #
93391778

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics